HeartWorks Featured on Before the Cure

Dr. Tim Nelson, HeartWorks CEO, featured on the Before the Cure podcast episode cover art

HeartWorks Featured on Before the Cure

What does it take to pursue a cure when the path forward requires building something entirely new?

HeartWorks CEO and Co-founder Dr. Tim Nelson recently joined hosts Timothy Wheeler and David Tsai on Before the Cure, a podcast dedicated to the people, persistence, uncertainty, and ideas behind medical innovation.

In the episode, “Why Did a Doctor Buy a 600,000-Square-Foot Hospital for $1?”, Tim shares the story behind HeartWorks and the decisions that have shaped its approach to congenital heart disease. The conversation explores what it takes to move promising science toward patients, why the traditional pace of innovation isn’t good enough for families waiting for better options, and why HeartWorks continues to build the people, facilities, technology, and infrastructure needed to accelerate progress.

And, of course, they talk about the $1 hospital.

The conversation offers a look at the thinking behind HeartWorks and the belief that changing the future of congenital heart disease will require more than a single discovery. It requires building an entire platform capable of moving discoveries forward.

A huge thank you to Timothy Wheeler, David Tsai, and the entire Before the Cure team for the opportunity to share this story and for creating a platform dedicated to the people working toward breakthroughs long before the outcome is certain.

We hope you’ll take some time to listen to the conversation and learn more about why HeartWorks was built and where we’re headed next.

Listen to the full episode: Why Did a Doctor Buy a 600,000-Square-Foot Hospital for $1? | Dr. Tim Nelson

Share the Post:

Related Posts

catheter-based cardiac cell delivery technology

One Step Closer: HeartWorks Partners with SmartCella to Advance Cardiac Cell Delivery

Manufacturing personalized cardiac cells is one challenge. Getting them safely into the heart is another. HeartWorks has entered a licensing agreement with SmartCella, a Sweden-based biotech company, for its Extroducer® — a minimally invasive, catheter-based platform that could deliver cardiac cells directly to heart muscle without the need for open-heart surgery. Lab testing showed that our cardiac lineage cells maintained high viability through the delivery process, a key early milestone. Combined with reaching our first 100 biopsy participants, this partnership represents meaningful progress on the path to personalized CHD treatment.

Read More
Lori Riess and Drew Narwold, HeartWorks team members supporting The Co-op patient-driven research platform for congenital heart disease

Lori & Drew: Maximizing the Potential of the Co-op

Behind every patient who joins The Co-op @ HeartWorks, there’s a team making sure the
process is simple, the experience is supportive, and the information shared actually drives
research forward.
Meet two of the people making that happen:
Lori Reiss, Co-op Coordinator, is a personal point of contact for families who want to learn more,
get started, or simply have questions about what participation looks like. Drew Narwold works
behind the scenes to organize and analyze the data participants share — including helping
HeartWorks make smarter decisions about manufacturing personalized cardiac cells for our first
100 participants.
Together, they’re helping close the gap between patient experiences and scientific progress.

Read More

Send A Message

This field is for validation purposes and should be left unchanged.
Name(Required)
Please let us know what's on your mind. Have a question for us? Ask away.